[
  {
    "ts": "2025-10-31T23:35:38+00:00",
    "headline": "Closing Bell Movers: Amazon soars to all-time highs on earnings",
    "summary": "In the opening hour of the evening session, U.S. equity futures are notably higher, with S&P 500 up 0.5% and Nasdaq 100 contracts up 1.0%. In commodities, WTI Crude Oil is little changed just above $60 per barrel while precious metals are stronger for the 3rd day in a row – Gold is above $4,040 and Silver is approaching $49 per ounce. A strong slate of quarterly Tech results are helping stock futures restore positive sentiment in the segment that was wounded on Thursday by more dubious results o",
    "url": "https://finance.yahoo.com/news/closing-bell-movers-amazon-soars-233538498.html",
    "source": "TipRanks",
    "provider": "yfinance",
    "raw": {
      "id": "6db6860c-7fc6-309d-9b56-85fb90941668",
      "content": {
        "id": "6db6860c-7fc6-309d-9b56-85fb90941668",
        "contentType": "STORY",
        "title": "Closing Bell Movers: Amazon soars to all-time highs on earnings",
        "description": "",
        "summary": "In the opening hour of the evening session, U.S. equity futures are notably higher, with S&P 500 up 0.5% and Nasdaq 100 contracts up 1.0%. In commodities, WTI Crude Oil is little changed just above $60 per barrel while precious metals are stronger for the 3rd day in a row – Gold is above $4,040 and Silver is approaching $49 per ounce. A strong slate of quarterly Tech results are helping stock futures restore positive sentiment in the segment that was wounded on Thursday by more dubious results o",
        "pubDate": "2025-10-31T23:35:38Z",
        "displayTime": "2025-10-31T23:35:38Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/tipranks_452/c4f6c07e08d4829fbea65fa26099a197",
          "originalWidth": 192,
          "originalHeight": 192,
          "caption": "https://www.tipranks.com/news/the-fly/closing-bell-movers-amazon-soars-to-all-time-highs-on-earnings-thefly",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZmeJPv9d6gKGE1bbiJoSwg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/c4f6c07e08d4829fbea65fa26099a197.cf.webp",
              "width": 192,
              "height": 192,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_VlCSLzqaaBkrggeNUiouw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/c4f6c07e08d4829fbea65fa26099a197.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TipRanks",
          "url": "https://www.tipranks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/closing-bell-movers-amazon-soars-233538498.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/closing-bell-movers-amazon-soars-233538498.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            },
            {
              "symbol": "TEAM"
            },
            {
              "symbol": "FORM"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "TWLO"
            },
            {
              "symbol": "ROKU"
            },
            {
              "symbol": "COIN"
            },
            {
              "symbol": "ILMN"
            },
            {
              "symbol": "SYK"
            },
            {
              "symbol": "WDC"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "IRTC"
            },
            {
              "symbol": "DXCM"
            },
            {
              "symbol": "Z"
            },
            {
              "symbol": "ZG"
            },
            {
              "symbol": "COLM"
            },
            {
              "symbol": "FSLR"
            },
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "RDDT"
            },
            {
              "symbol": "TVTX"
            },
            {
              "symbol": "SPSC"
            },
            {
              "symbol": "RYAN"
            },
            {
              "symbol": "NET"
            },
            {
              "symbol": "IR"
            },
            {
              "symbol": "RKT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-31T20:03:03+00:00",
    "headline": "Gilead Stock Reverses; Why Its Buy-Side Miss Isn't The End For Its New HIV Shot",
    "summary": "Gilead stock reversed higher on smaller losses Friday as analysts noted encouraging indicators for its newly approved HIV prevention shot.",
    "url": "https://www.investors.com/news/technology/gilead-sciences-earnings-gilead-stock-q3-2025/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "24da1617-e882-337a-8d5e-a8f4b585015f",
      "content": {
        "id": "24da1617-e882-337a-8d5e-a8f4b585015f",
        "contentType": "STORY",
        "title": "Gilead Stock Reverses; Why Its Buy-Side Miss Isn't The End For Its New HIV Shot",
        "description": "",
        "summary": "Gilead stock reversed higher on smaller losses Friday as analysts noted encouraging indicators for its newly approved HIV prevention shot.",
        "pubDate": "2025-10-31T20:03:03Z",
        "displayTime": "2025-10-31T20:03:03Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/24da1617-e882-337a-8d5e-a8f4b585015f/gilead-stock-reverses-why.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/32b4af924bb2a92db4738e475b47120e",
          "originalWidth": 1000,
          "originalHeight": 565,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Syzb_GYUdYGAMf157djXWA--~B/aD01NjU7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/32b4af924bb2a92db4738e475b47120e.cf.webp",
              "width": 1000,
              "height": 565,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/s7horPaK_6m5p7WS_RtXIw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/32b4af924bb2a92db4738e475b47120e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/gilead-sciences-earnings-gilead-stock-q3-2025/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-31T14:20:00+00:00",
    "headline": "GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow",
    "summary": "Gilead posts upbeat Q3 results on strong HIV and Livdelzi sales, but shares slip despite earnings and revenue beats.",
    "url": "https://finance.yahoo.com/news/gild-q3-earnings-sales-beat-142000428.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "26fac3b6-47d4-38ea-949b-cf35502f50d3",
      "content": {
        "id": "26fac3b6-47d4-38ea-949b-cf35502f50d3",
        "contentType": "STORY",
        "title": "GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow",
        "description": "",
        "summary": "Gilead posts upbeat Q3 results on strong HIV and Livdelzi sales, but shares slip despite earnings and revenue beats.",
        "pubDate": "2025-10-31T14:20:00Z",
        "displayTime": "2025-10-31T14:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/be92d53349e9fe392d730a7a723f3358",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SboUKe_W9067T1LVniRLdQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/be92d53349e9fe392d730a7a723f3358.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uw0pEVH0XNH4aS_Qhxpglg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/be92d53349e9fe392d730a7a723f3358.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gild-q3-earnings-sales-beat-142000428.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gild-q3-earnings-sales-beat-142000428.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-31T13:00:02+00:00",
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
    "url": "https://finance.yahoo.com/news/2-medical-stocks-could-beat-130002066.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "403cff99-26ff-3518-8835-c58c147dd154",
      "content": {
        "id": "403cff99-26ff-3518-8835-c58c147dd154",
        "contentType": "STORY",
        "title": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
        "description": "",
        "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
        "pubDate": "2025-10-31T13:00:02Z",
        "displayTime": "2025-10-31T13:00:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f",
          "originalWidth": 900,
          "originalHeight": 601,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmhBrL1RMEs5kGBSUQzx5g--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f.cf.webp",
              "width": 900,
              "height": 601,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CMWRvhn58nUVOwpQjtvr2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/2-medical-stocks-could-beat-130002066.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-medical-stocks-could-beat-130002066.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": null,
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-31T12:40:45+00:00",
    "headline": "GILD Q3 Deep Dive: HIV and Liver Disease Strength Offset Oncology Headwinds",
    "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 3% year on year to $7.77 billion. On the other hand, the company’s full-year revenue guidance of $28.55 billion at the midpoint came in 1.1% below analysts’ estimates. Its non-GAAP profit of $2.47 per share was 15.7% above analysts’ consensus estimates.",
    "url": "https://finance.yahoo.com/news/gild-q3-deep-dive-hiv-124045698.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "76cbb575-54be-3c42-916e-02fc2c552ccc",
      "content": {
        "id": "76cbb575-54be-3c42-916e-02fc2c552ccc",
        "contentType": "STORY",
        "title": "GILD Q3 Deep Dive: HIV and Liver Disease Strength Offset Oncology Headwinds",
        "description": "",
        "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 3% year on year to $7.77 billion. On the other hand, the company’s full-year revenue guidance of $28.55 billion at the midpoint came in 1.1% below analysts’ estimates. Its non-GAAP profit of $2.47 per share was 15.7% above analysts’ consensus estimates.",
        "pubDate": "2025-10-31T12:40:45Z",
        "displayTime": "2025-10-31T12:40:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "GILD Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7IhZSScYZ4CvnQJJpve_Dg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cv.0mSrHV7hG2Zeh2xc10A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gild-q3-deep-dive-hiv-124045698.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gild-q3-deep-dive-hiv-124045698.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-31T12:00:00+00:00",
    "headline": "HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead",
    "summary": "NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and certain of its assets related to HOOKIPA’s HB-500 program to Gilead Sciences, Inc. (“Gilead”). In connection with the consideration and evaluation of HOOKIPA’s long-term prospects and strategies by HOOKIPA’s board of directors, on May 21, 2025 HOOKIPA entered into an asset purchase agreement (“Asset Pu",
    "url": "https://finance.yahoo.com/news/hookipa-pharma-announces-completion-sale-120000288.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "b2459210-9ed7-31df-956d-656d284637cf",
      "content": {
        "id": "b2459210-9ed7-31df-956d-656d284637cf",
        "contentType": "STORY",
        "title": "HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead",
        "description": "",
        "summary": "NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and certain of its assets related to HOOKIPA’s HB-500 program to Gilead Sciences, Inc. (“Gilead”). In connection with the consideration and evaluation of HOOKIPA’s long-term prospects and strategies by HOOKIPA’s board of directors, on May 21, 2025 HOOKIPA entered into an asset purchase agreement (“Asset Pu",
        "pubDate": "2025-10-31T12:00:00Z",
        "displayTime": "2025-10-31T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d51d51e2b4a8372dc9e6035cfa2492f1",
          "originalWidth": 433,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MxCxcFBtxuVd_bau0tPA2A--~B/aD00MzI7dz00MzM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d51d51e2b4a8372dc9e6035cfa2492f1.cf.webp",
              "width": 433,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w3YcLVr_0sWz4Gb5c4j7tQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d51d51e2b4a8372dc9e6035cfa2492f1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/hookipa-pharma-announces-completion-sale-120000288.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/hookipa-pharma-announces-completion-sale-120000288.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HOOK"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-31T12:00:00+00:00",
    "headline": "Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)",
    "summary": "FOSTER CITY, Calif., October 31, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo® (lenacapavir), the company’s twice-yearly injectable HIV-1 capsid inhibitor that provides adults and adolescents (≥35kg) at risk of HIV-1 acquisition with a new, highly effective option for pre-exposure prophylaxis (PrEP) for the prevention of HIV. The award, which recognizes outstanding pharmaceuti",
    "url": "https://finance.yahoo.com/news/gilead-sciences-wins-prestigious-2025-120000284.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "7e3e8a7f-1346-31e0-90e5-88043a4b6b65",
      "content": {
        "id": "7e3e8a7f-1346-31e0-90e5-88043a4b6b65",
        "contentType": "STORY",
        "title": "Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)",
        "description": "",
        "summary": "FOSTER CITY, Calif., October 31, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo® (lenacapavir), the company’s twice-yearly injectable HIV-1 capsid inhibitor that provides adults and adolescents (≥35kg) at risk of HIV-1 acquisition with a new, highly effective option for pre-exposure prophylaxis (PrEP) for the prevention of HIV. The award, which recognizes outstanding pharmaceuti",
        "pubDate": "2025-10-31T12:00:00Z",
        "displayTime": "2025-10-31T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/9ecfab602c789c1f38f7d61ecf9e619a",
          "originalWidth": 1728,
          "originalHeight": 576,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vJpuIGf.SDTggyY4TBWN3A--~B/aD01NzY7dz0xNzI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/9ecfab602c789c1f38f7d61ecf9e619a.cf.webp",
              "width": 1728,
              "height": 576,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MrICbaSb6nuNZ5yE8mm9Qw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/9ecfab602c789c1f38f7d61ecf9e619a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-wins-prestigious-2025-120000284.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-wins-prestigious-2025-120000284.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-31T09:44:47+00:00",
    "headline": "Is Wall Street Bullish or Bearish on Gilead Sciences Stock?",
    "summary": "Gilead Sciences has outpaced the broader market over the past year, and analysts maintain a fairly bullish outlook on the stock’s future performance.",
    "url": "https://www.barchart.com/story/news/35821438/is-wall-street-bullish-or-bearish-on-gilead-sciences-stock",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "a5a026f5-7235-395f-9387-232cf49fc2ae",
      "content": {
        "id": "a5a026f5-7235-395f-9387-232cf49fc2ae",
        "contentType": "STORY",
        "title": "Is Wall Street Bullish or Bearish on Gilead Sciences Stock?",
        "description": "",
        "summary": "Gilead Sciences has outpaced the broader market over the past year, and analysts maintain a fairly bullish outlook on the stock’s future performance.",
        "pubDate": "2025-10-31T09:44:47Z",
        "displayTime": "2025-10-31T09:44:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/31e98582ac8bd44916a76a1228c3e08e",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Gilead Sciences, Inc_ logo and vials -by Melnikov Dmitriy via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4ZVwOdK61Xg8o5Mr50Lzcw--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/31e98582ac8bd44916a76a1228c3e08e.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mZU7yS6z0JfGzyXqezjBuQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/31e98582ac8bd44916a76a1228c3e08e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/35821438/is-wall-street-bullish-or-bearish-on-gilead-sciences-stock",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/wall-street-bullish-bearish-gilead-094447791.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-31T03:00:57+00:00",
    "headline": "Gilead Sciences Inc (GILD) Q3 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth ...",
    "summary": "Gilead Sciences Inc (GILD) reports robust performance in HIV therapies, offsetting challenges in Veklury and cell therapy sales.",
    "url": "https://finance.yahoo.com/news/gilead-sciences-inc-gild-q3-030057459.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "7c87dec4-8138-399e-89b3-a965e91306fa",
      "content": {
        "id": "7c87dec4-8138-399e-89b3-a965e91306fa",
        "contentType": "STORY",
        "title": "Gilead Sciences Inc (GILD) Q3 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth ...",
        "description": "",
        "summary": "Gilead Sciences Inc (GILD) reports robust performance in HIV therapies, offsetting challenges in Veklury and cell therapy sales.",
        "pubDate": "2025-10-31T03:00:57Z",
        "displayTime": "2025-10-31T03:00:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/021491fd49d24965c71b26be3366a968",
          "originalWidth": 320,
          "originalHeight": 320,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7xK8bw6y1aG7.53HdIqj_g--~B/aD0zMjA7dz0zMjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/021491fd49d24965c71b26be3366a968.cf.webp",
              "width": 320,
              "height": 320,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/te0FsiWvGQ8ceh7mT7s8iw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/021491fd49d24965c71b26be3366a968.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-inc-gild-q3-030057459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-inc-gild-q3-030057459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]